Adalimumab monotherapy and combination with methotrexate showed similar drug survival and PASI75 response rates in plaque psoriasis patients. Methotrexate reduced antidrug antibody levels but did not ...

They received either sarilumab or adalimumab every 2 weeks. Researchers observed improvements with sarilumab as early as week 4; significantly greater proportions of sarilumab- vs adalimumab-treated ...

Greater rates of patients with PsO achieved concurrent complete skin and nail clearance with bimekizumab vs adalimumab, ustekinumab, and secukinumab.

PHILADELPHIA -- Pfizer has made the case for gaining the coveted "interchangeability" status for its adalimumab biosimilar (Abrilada), a study presented here suggested. A pivotal trial involving ...

Boston Oncology Arabia and LCGPA sign agreement to localize biologic manufacturing in Saudi Arabia, advancing Vision 2030 and ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window Adalimumab ...

“Although SEAVUE did not demonstrate superior efficacy of ustekinumab over adalimumab, both agents showed surprisingly high rates of clinical remission at 1 year of treatment in this population of ...

Please provide your email address to receive an email when new articles are posted on . In the randomized, double-blind phase 3 study ENVISION I, Croft and colleagues analyzed data from 93 children ...

Chronic plaque psoriasis is a condition in which epithelial cells are over produced and form a well-defined site. The redness is often covered with silvery scales of skin. The cause of this type of ...

On October 5, Celltrion Healthcare Co. announced that it has signed a contract with Ventegra, a major U.S. Medical Benefits Manager (MBM) “who administers pharmacy benefits through its Pharmacy ...

Background We report on a patient with rheumatoid arthritis (RA) who was treated with adalimumab and retrospectively diagnosed as having a multiple myeloma. Investigations In addition to the ...

The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a citrate-free, high-concentration formulation, the manufacturer, Celltrion USA, announced today. It ...